A novel peptide design aids in the expression and its simplified process of manufacturing of Insulin Glargine in Pichia pastoris.
Sign Up to like & getrecommendations! Published in 2021 at "Applied microbiology and biotechnology"
DOI: 10.1007/s00253-021-11224-y
Abstract: Manufacturing of insulin and its analogues relied upon in vitro enzymatic cleavages of its precursor forms (single chain precursor, SCP) at both ends of a connecting peptide (C-peptide) that links the respective B-chain and A-chains… read more here.
Keywords: insulin; insulin glargine; process; precursor ... See more keywords
Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Acta Diabetologica"
DOI: 10.1007/s00592-018-1258-0
Abstract: AimsTo assess the effectiveness of insulin glargine 300 ui/ml (Gla-300) compared with insulin glargine 100 ui/ml (Gla-100) on reducing nocturnal hypoglycemia and improving glycemic control in type 1 and type 2 diabetes patients.MethodsWe systematically searched… read more here.
Keywords: type; insulin glargine; hypoglycemia; nocturnal hypoglycemia ... See more keywords
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Sign Up to like & getrecommendations! Published in 2019 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2019.06.006
Abstract: OBJECTIVE To explore the beneficial effects of dapagliflozin and/or insulin glargine on the pancreatic beta cell mass and hepatic steatosis in db/db mice. METHODS Six-week-old db/db mice were assigned to one of four groups: untreated… read more here.
Keywords: glargine; cell mass; insulin glargine; gla ... See more keywords
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2018.1513406
Abstract: Abstract Aims: The clinical and economic impact of diabetes is growing in the US. Choosing therapies that are both effective and cost-effective is becoming increasingly important. The aim of the present analysis was to assess… read more here.
Keywords: plus insulin; glargine u100; insulin glargine; insulin aspart ... See more keywords
Introduction of biosimilar insulins in Europe
Sign Up to like & getrecommendations! Published in 2017 at "Diabetic Medicine"
DOI: 10.1111/dme.13400
Abstract: Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar®), in 2014 expanded the treatment options available to people with diabetes. As biosimilar insulin products come to market, it is important to… read more here.
Keywords: insulin; insulins europe; insulin glargine; biosimilar insulin ... See more keywords
Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13535
Abstract: For patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control, addition of basal insulin is recommended, but titration and optimization of basal insulin therapy in primary care is not well understood. We conducted… read more here.
Keywords: titration optimization; insulin; titration; glargine 100 ... See more keywords
Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14674
Abstract: To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus®]) in Chinese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). read more here.
Keywords: chinese patients; insulin; immunogenicity ly2963016; insulin glargine ... See more keywords
Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14929
Abstract: To determine the effectiveness and safety of early combination of insulin glargine with intravenous (IV) insulin infusion compared with IV insulin infusion alone in the management of diabetic ketoacidosis (DKA). read more here.
Keywords: insulin infusion; insulin glargine; effectiveness safety; safety early ... See more keywords
Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.14377
Abstract: Insulin degludec/aspart (IDegAsp) and insulin glargine U300 (IGlarU300) have recently emerged as popular new‐generation insulin analogues. The aim of this real‐life study was to investigate the patient profiles in which IGlarU300 and IDegAsp were preferred… read more here.
Keywords: insulin; degludec aspart; insulin glargine; glargine u300 ... See more keywords
Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Open"
DOI: 10.1136/bmjopen-2019-033659
Abstract: Introduction Type 2 diabetes mellitus (T2DM) is a common and heterogeneous disease. Using advanced analytic approaches to explore real-world data may identify different disease characteristics, responses to treatment and progression patterns. Insulin glargine 300 units/mL… read more here.
Keywords: methodology; analysis; insulin glargine; glargine 300 ... See more keywords
Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Diabetes and Endocrinology"
DOI: 10.1186/s40842-018-0059-2
Abstract: BackgroundTo identify baseline/clinical characteristics associated with clinically meaningful responses to insulin glargine 100 U/mL (IGlar) in insulin-naive people with type 2 diabetes mellitus (T2DM).MethodsIndividual participant data were pooled from 3 randomized trials to compare baseline characteristics… read more here.
Keywords: insulin; response; people type; insulin glargine ... See more keywords